Charles Schwab’s Xenon Pharmaceuticals XENE Stock Holding History

Charles Schwab’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.1M	Buy	249,473 +60,393	+32%	+$3.35M	﹤0.01%	1964
2026 Q1	$11M	Buy	189,080 +21	+0%	+$968	﹤0.01%	2051
2025 Q4	$8.47M	Buy	189,059 +312	+0.2%	+$13.1K	﹤0.01%	2213
2025 Q3	$7.58M	Sell	188,747 -3,495	-2%	-$123K	﹤0.01%	2242
2025 Q2	$6.02M	Buy	+192,242	New	+$6.27M	﹤0.01%	2254

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Charles Schwab's XENE Position: Q2 2026 in Review

Charles Schwab increased its Xenon Pharmaceuticals (XENE) stake by 32% in Q2 2026, buying an estimated $3.35M and bringing the position to 249,473 shares worth $15.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1964.

Charles Schwab first reported a position in XENE in Q2 2025 and has held it in 5 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Charles Schwab held 249,473 shares of Xenon Pharmaceuticals worth $15.1M as of Q2 2026.
Charles Schwab bought 60,393 Xenon Pharmaceuticals shares in Q2 2026, an estimated $3.35M.
Xenon Pharmaceuticals made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1964 holding.
Charles Schwab first reported a position in Xenon Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.